Singh Biotechnology, LLC. (SBT) is a biotech organization in the business of discovering and developing unique and proprietary therapeutic agents for the treatment of a variety of cancers and autoimmune diseases by leveraging a novel technology platform.

Using this technology platform SBT has been able to generate therapeutic agents that specifically target intracellular molecules of interest, which are mutated, hyper expressed, or play an important role in the pathogenesis of diseases.

Our proprietary technology and therapeutic agent's have enabled us to specifically target and inhibit:

  • Signal transducer and activator of transcription 3 (STAT3)
  • Mutated KRAS
  • Tumor Necrosis Factor-alpha (TNF-alpha)

Currently Singh Biotechnology, LLC. has a proprietary anti-mutated KRAS inhibitor and three anti-TNF-alpha inhibitors in preclinical studies. SBT’s lead therapeutic agent, anti-STAT3 inhibitor (SBT-100) is near completion of its preclinical studies.

Singh Biotechnology, LLC. has patented its novel therapeutic disease agents which are ‘small’ in size when compared to other traditional pharmaceutical compounds that target cell membrane receptors. 

  • This size difference allows our proprietary agents to penetrate deeper into body tissues.
  • Our therapeutic agents have the same degree of binding affinity for its target molecule as traditional pharmaceutical compounds.

  • Due to our proprietary therapeutic agents unique size and structure of its binding regions, we are able to access binding sites on targets where the bulkier larger pharmaceutical compounds cannot access.
  • As an added benefit, the ‘small’ size and structure of our therapeutic agent makes it easier to produce and less expensive to manufacture.



Science is a series of judgments, revised without ceasing.

- Pierre Emile Duclaux